目的 探讨儿童清肺口服液联合丙卡特罗治疗小儿喘息性支气管炎的临床疗效。方法 回顾性分析2022年1月—2024年12月北京市通州区妇幼保健院收治的112例喘息性支气管炎患儿的病例资料，按治疗方法分成对照组和治疗组，每组各56例。对照组口服盐酸丙卡特罗口服溶液，0.25 mL/kg，2次/d。治疗组在对照组用药基础上口服儿童清肺口服液，1支/次，3次/d。两组患儿治疗1周。观察两组患儿临床疗效，比较治疗前后两组患儿症状消失时间，肺功能指标潮气量（VT）、呼吸频率（BF）、周边弹性阻力，及中性粒细胞与淋巴细胞比值（NLR）、嗜酸性粒细胞（EOS）和血清C反应蛋白（CRP）、降钙素原（PCT）水平。结果 治疗后，治疗组总有效率（96.43%）明显高于对照组（85.71%，P＜0.05）。治疗后，治疗组喘息、咳嗽、发热、咯痰、肺部啰音消失时间比对照组都明显缩短（P＜0.05）。治疗后，两组肺功能指标VT都升高，而BF、周边弹性阻力均降低（P＜0.05），且治疗组肺功能指标显著好于对照组（P＜0.05）。治疗后，两组炎症指标NLR、EOS和血清CRP、PCT水平都下降（P＜0.05），且与对照组相比，治疗组降低更显著（P＜0.05）。结论 儿童清肺口服液联合丙卡特罗治疗小儿喘息性支气管炎，能提高炎症损害和症状控制的效率，减少气道和肺功能损伤，改善整体治疗效果。

Objective To investigate the clinical efficacy of Ertong Qingfei Oral Liquid combined with procaterol in treatment of children with asthmatic bronchitis. Methods The clinical data of children (112 cases) with asthmatic bronchitis in Tongzhou District Maternal and Child Health Hospital of Beijing from January 2022 to December 2024 were analyzed retrospectively. They were divided into control and treatment group based on different treatments, and each group had 56 cases. Children in the control group were po administered with Procaterol Hydrochloride Oral Solution, 0.25 mL/kg, twice daily. Children in the treatment group were po administered with Ertong Qingfei Oral Liquid on the basis of the control group, 1 vial/time, three times daily. Children in two groups were treated for 1 week. After treatment, the clinical evaluations were evaluated, and the symptom disappearance time, and the lung function indexes of VT, BF and peripheral elastic resistance, the levels of NLR, EOS, serum CRP and PCT in two groups before and after treatment were compared. Results After treatment, the total effective rate in the treatment group (96.43%) was significantly higher than that in the control group (85.71%, P < 0.05). After treatment, the disappearance time of wheezing, coughing, fever, expectoration, and pulmonary rales in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, the pulmonary function index VT was significantly increased in two groups, while BF and peripheral elastic resistance were significantly decreased (P < 0.05). The pulmonary function index in the treatment group was significantly better than that in the control group (P < 0.05). After treatment, the levels of inflammatory indicators NLR, EOS, and serum CRP and PCT in both groups decreased (P < 0.05), and compared with the control group, the reduction was more significant in the treatment group (P < 0.05). Conclusion Ertong Qingfei Oral Liquid combined with procaterol in treatment of asthmatic bronchitis in children can improve the efficiency of inflammation damage and symptom control, reduce airway and lung function damage, and promote the improvement of the overall treatment effect.

R974

北京市通州区科技计划项目（KJ2022CX051）